Market Research Report
Biosimilars: US Payer Perspectives (2018)
|Published by||FirstWord||Product code||328749|
Delivery time: 1-2 business days
|Biosimilars: US Payer Perspectives (2018)|
|Published: April 1, 2018||Content info:||
US payers eye European biologics market with envy
Biosimilars may be a roaring success in Europe but the picture in the US couldn't be more different. Once hailed as a solution to stem the tide of soaring drug spending, in the cold light of day, the US biosimilars market has failed to meet expectations. Payers are frustrated. Can the cycle of endless litigation and aggressive commercial tactics be broken? How are payers coping? What do these key stakeholders need to happen next?
Our professional researchers have just interviewed 10 senior level payers, raising the key issues from the last 12 months and revealing their views on potential market evolution.
What to expect from this report
Our reports are entirely based on the latest thinking, gathered in the last month (April 2018). You won't find entrenched perceptions, old data and out-of-date opinions. Instead, Biosimilars: US Payer Perspectives gives detailed insight into the latest thought processes and actions of senior payers. It's exactly what you need to know.
Example insight included in Biosimilars: US Payer Perspectives
Payers have devised strategies to encourage the adoption of biosimilars. Currently, payers require prior authorisations, and, in the future, they may introduce steps through biosimilars before allowing access to branded originators. In the recent past, large payer organisations have excluded branded drugs from their formularies and adopted biosimilars to encourage biosimilar uptake, a practice that many payers believe will become more challenging to apply as more biosimilars are approved and launched in the US.
Example quote included in Biosimilars: US Payer Perspectives
"At this point, these [biosimilars] are all on the same tier. They're considered preferred specialty drugs, so other than stepping through first lines of therapy, there is not step therapy through the biosimilar to get to the brand at this point. It will evolve with the real-world data. It will evolve if the interchangeability designation is there. Then it will evolve as the manufacturers and the payers begin to negotiate on the pricing."
The expert panel for Biosimilars: US Payer Perspectives
We only interviewed senior payers with current and relevant experience-and all are involved in formulary decisions related to biosimilars (e.g. filgrastim biosimilars [Zarxio], insulin glargine copies [Basaglar] and infliximab biosimilars [Inflectra, Renflexis]).
Why buy now?
Poor uptake of biosimilars cannot continue forever. Frustration levels have reached a critical point and the general feeling among payers is that change is not only inevitable, it can be driven by them too. This report gives you the inside track on the current mood as well as what payers expect will happen next.
Why FirstWord reports are different